Tirzepatide
COMMIT-CD
Eli Lilly · Phase 3 · Recruiting · Enrollment 290
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Mirikizumab + Tirzepatide | n/r | n/r | n/r | n/r |
| Mirikizumab + Placebo | n/r | n/r | n/r | n/r |
Not shown
- Mirikizumab + Tirzepatide: endpoint not reported
- Mirikizumab + Placebo: endpoint not reported